ORYZON to Present New Clinical Data and Corporate Updates at International Conferences in September and October
Retrieved on:
Wednesday, September 22, 2021
ISIN, Person, Conference, Precision medicine, Structure, Spanish, PMS, Communication, Genomics, Kabuki syndrome, HOPE, EST, Safety, ORY, Public expenditure, Research, Mercado, BPD, BIO, Hospital Universitario La Paz, Development of the nervous system, Prospectus, Phenotype, Borderline personality disorder, CNS, Clinical trial, RRMS, Patient, ECNP, Pediatrics, Sale, CNMV, Neuroscience, Hospital das ClĂnicas, Functional genomics, SPMS, Forward-looking statement, LSD1, Kennedy Krieger Institute, GLOBE, Department, Treatment, KOL, European Committee for Sports History, Assistant, Congress, Central nervous system disease, Mission statement, Sclerosis (medicine), Psychiatry, Degeneration theory, International Conference on Nuclear Disarmament, Oslo, 2008, CET, Schizophrenia, Pharmaceutical industry, Medical device
Oryzon will present preliminary data from the ongoing collaboration with INGEMM in Phelan McDermid Syndrome (PMS) at the International Conference on Autism, ICA-2021, which will be held on September 23-24.
Key Points:
- Oryzon will present preliminary data from the ongoing collaboration with INGEMM in Phelan McDermid Syndrome (PMS) at the International Conference on Autism, ICA-2021, which will be held on September 23-24.
- The communication entitled "Phenotype and Psychometric Characterization of Phelan McDermid Syndrome Patients" will be presented by Dr. Carlos Buesa, Oryzons CEO.
- Executive directors of the company will attend the BIO Spain 2021 event, which will take place September 27-October 1.
- The company will moderate a KOL panel discussion on precision medicine therapeutic approaches for CNS disorders and the potential of LSD1 inhibitors like vafidemstat.